These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Study on effect of baoyuan qiangshen tablet no. I in prolongating interval of hemodialysis in patients of terminal-stage of renal disease].
    Author: Zhu PJ, Li YS.
    Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi; 1996 Jun; 16(6):326-9. PubMed ID: 9387757.
    Abstract:
    Twenty cases of terminal stage of renal disease (TSRD) were treated with Baoyuan Qiangshen Tablet No. I(BYQS I) combined with hemodialysis once every 5 days (TCM-WM group) was observed and compared with patients treated with routine hemodialysis (once every 3 days) only (control group). Results showed that the increasing extents of serum creatinine, blood urea nitrogen of TCM-WM group at dialysis interval were all lower than that of control group (P < 0.01). After 3 months' treatment, serum creatinine, blood urea nitrogen of TCM-WM group were lower than that before treatment, plasma albumin, lipoprotein, urine level of prostaglandin and anemia were all improved to varies extent, but the creatinine clearance rate was unchanged. The author considered that BYQS I could prolong the interval and reduce the times of dialysis by way of regulating the lipid metabolism disorder, improving pathological change of kidney and protect function of residual kidney unit, and above-mentioned therapeutic method is a good programm of integrated TCM-WM in treating TSRD.
    [Abstract] [Full Text] [Related] [New Search]